Analysis of Hospital Admissions Related to Adverse Drug Events Using ADE Signals
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sukhyang LEE | - |
dc.contributor.author | Hye Young KIM | - |
dc.contributor.author | Kyung-Hoon LEE | - |
dc.contributor.author | Hyun Kyung KOO | - |
dc.contributor.author | Yoon KIM | - |
dc.date.available | 2021-02-22T15:31:42Z | - |
dc.date.issued | 2006-03 | - |
dc.identifier.issn | 1976-9148 | - |
dc.identifier.issn | 2005-4483 | - |
dc.identifier.uri | https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/15224 | - |
dc.description.abstract | The objective of the study was to evaluate the bioequivalency betwen the RozidTM Tablet (IlhwaPharm. Co., Ltd.) as a test formulation and the Rulid | - |
dc.format.extent | 10 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 한국응용약물학회 | - |
dc.title | Analysis of Hospital Admissions Related to Adverse Drug Events Using ADE Signals | - |
dc.title.alternative | Analysis of Hospital Admissions Related to Adverse Drug Events Using ADE Signals | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.bibliographicCitation | Biomolecules & Therapeutics, v.14, no.1, pp 56 - 65 | - |
dc.citation.title | Biomolecules & Therapeutics | - |
dc.citation.volume | 14 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 56 | - |
dc.citation.endPage | 65 | - |
dc.identifier.kciid | ART001006479 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | kci | - |
dc.identifier.url | https://kiss.kstudy.com/Detail/Ar?key=2524952 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Sookmyung Women's University. Cheongpa-ro 47-gil 100 (Cheongpa-dong 2ga), Yongsan-gu, Seoul, 04310, Korea02-710-9127
Copyright©Sookmyung Women's University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.